Passion for Innovation. Compassion for Patients.™
Daiichi Sankyo Europe GmbH
Dear User,
This website provides you with information only for healthcare professionals. According to the drug
promotion code, we are only able to allow healthcare professionals like physicians and pharmacists to have
full access to our website. To visit our page please login.
European News
Daiichi Sankyo and AstraZeneca Enter New Global Development and Commercialization Collaboration for Daiichi Sankyo’s ADC DS-1062
Daiichi Sankyo
2020-08-03 09:16:13
Daiichi Sankyo and AstraZeneca Enter New Global Development and Commercialization Collaboration for Daiichi
Real-world edoxaban VTE data show low rates of bleeding and VTE events reported after 12 months of edoxaban treatment
Daiichi Sankyo
2020-07-28 17:37:28
Real-world edoxaban VTE data show low rates of bleeding and VTE events reported after 12 months of edoxaban
EMA Validates and Grants Accelerated Assessment for Trastuzumab Deruxtecan for the Treatment of HER2 Positive Metastatic Breast Cancer
Daiichi Sankyo
2020-08-03 09:20:19
EMA Validates and Grants Accelerated Assessment for Trastuzumab Deruxtecan for the Treatment of HER2 Positive
Daiichi Sankyo’s SANTORINI study gets underway, investigating cholesterol care across Europe
Daiichi Sankyo
2020-07-24 10:21:18
Daiichi Sankyo’s SANTORINI study gets underway, investigating cholesterol care across Europe
Daiichi Sankyo Announces Clinical Research Collaboration to Evaluate DS-1062 in Combination with KEYTRUDA® (pembrolizumab) in Metastatic Non-Small Cell Lung Cancer
Daiichi Sankyo
2020-07-24 10:25:56
Daiichi Sankyo Announces Clinical Research Collaboration to Evaluate DS-1062 in Combination with KEYTRUDA®
ENHERTU® Demonstrated Meaningful Clinical Activity in Patients with HER2 Mutant Non-Small Cell Lung Cancer in Interim Analysis of Phase 2 DESTINY-Lung01 Trial
Daiichi Sankyo
2020-08-03 09:20:43
ENHERTU® Demonstrated Meaningful Clinical Activity in Patients with HER2 Mutant Non-Small Cell Lung Cancer in
ENHERTU® Achieved a Tumor Response Rate of 45.3% in Patients with HER2 Positive Metastatic Colorectal Cancer in Phase 2 DESTINY-CRC01 Trial
Daiichi Sankyo
2020-08-03 09:21:42
ENHERTU® Achieved a Tumor Response Rate of 45.3% in Patients with HER2 Positive Metastatic Colorectal Cancer
ENHERTU® Significantly Improved Tumor Response Rate and Overall Survival in HER2 Positive Metastatic Gastric Cancer in Pivotal Phase 2 DESTINY-Gastric01 Trial
Daiichi Sankyo
2020-08-03 09:22:02
ENHERTU® Significantly Improved Tumor Response Rate and Overall Survival in HER2 Positive Metastatic Gastric
ENHERTU® Granted Orphan Drug Designation in the U.S. for Gastric Cancer
Daiichi Sankyo
2020-08-03 09:22:22
ENHERTU® Granted Orphan Drug Designation in the U.S. for Gastric Cancer
Daiichi Sankyo Initiates Clinical Trial with 5th DXd ADC, DS-6157, in Collaboration with Sarah Cannon Research Institute
Daiichi Sankyo
2020-07-24 10:37:21
Daiichi Sankyo Initiates Clinical Trial with 5th DXd ADC, DS-6157, in Collaboration with Sarah Cannon Research
More Stories
